Treatment of MEK inhibitor‐induced paronychia with doxycycline
A 12‐year‐old girl with neurofibromatosis type 1 and a large facial plexiform neurofibroma had been participating in a selumetinib clinical trial for the past 5 years. Despite decreased tumor size, she developed recalcitrant selumetinib‐induced paronychia. Various antibiotics, topical medications, and surgeries were only minimally effective. Full‐dose doxycycline resolved the paronychia, and sub‐antimicrobial dosing has prevented recurrences for several months, permitting her to continue her selumetinib course.
No Supplementary Data
No Article Media